Study Identifies Altered Immune Signaling Pathway in Brain Cells from People with Bipolar Disorder
Researchers using iPSC-derived brain cells from people with bipolar disorder found that the toll-like receptor signaling pathway—which plays a role in immune function—is downregulated compared to controls. The study analyzed whole transcriptome data from 12 bipolar disorder participants and 12 controls, identifying 191 enriched pathways with focus on immune dysregulation. The findings suggest immune system dysfunction may contribute to bipolar disorder's biological mechanisms, potentially opening new research directions for understanding the condition.
Scientists conducted whole transcriptome sequencing on iPSC-derived cortical networks (co-cultures of neurons and astrocytes) from 12 people with bipolar disorder and 12 controls without mental health disorders. Using blood cells reprogrammed into induced pluripotent stem cells, researchers differentiated them into neural progenitor cells that matured into functional brain tissue. Differential expression analysis identified 191 enriched pathways in bipolar disorder samples, with particular attention to the toll-like receptor signaling pathway, which was found to be downregulated. The results suggest profound immune dysregulation in bipolar disorder, positioning the immune system as a complex signaling network relevant to the disorder's pathophysiology. This iPSC-based approach allows researchers to study living human brain cells while controlling for genetic background, offering a unique window into disease mechanisms.
What's missing
The study's limitations include the relatively small sample size (12 per group), which may limit generalizability; the cross-sectional design, which cannot establish causation; and the in vitro model system, which may not fully recapitulate the complexity of bipolar disorder in living brains. The authors do not discuss whether findings are specific to bipolar disorder or may also occur in other psychiatric conditions, nor do they provide information on participant demographics, medication status, or clinical characteristics that could influence results.
What different sources said
- bioRxivCenter
The toll-like receptor signalling pathway is altered in iPSC-derived cortical networks from people with bipolar disorder.
Related
Study Maps Somatic Mutations in B Cells of Systemic Lupus Erythematosus Patients, Linking Genetic Changes to Disease Progression
Researchers analyzed somatic mutations across B-cell subsets in 35 systemic lupus erythematosus (SLE) patients and found that double-negative B cells accumulated the highest mutational burden. These mutations were associated with disease duration and immunosuppressive therapy rather than disease activity, and some mutations resembled those found in B-cell lymphomas. The findings suggest that chronic immune stimulation and therapeutic pressure drive clonal evolution in autoimmune disease, potentially explaining disease heterogeneity and progression.
Preserving Native Cellulose-Xylan Structure Enables High-Performance Sustainable Nanofibrils
Researchers developed an optimized method to isolate holocellulose nanofibrils (hCNFs) that preserves the native architecture of cellulose and xylan, mimicking the structural design of plant cell walls. The study used multiple plant systems including Arabidopsis mutants and Brassica napus straw to systematically determine how xylan composition and structure affect nanofibril properties. The findings demonstrate that maintaining native cellulose-hemicellulose interactions produces high-performance materials without harsh chemical treatments, offering a sustainable alternative to conventional nanocellulose production.
Study Identifies Galectin-3's Role in Gastric Metaplasia Development Through Cathartocytosis
Researchers found that galectin-3, a protein upregulated in precancerous tissue changes, facilitates a cellular process called cathartocytosis that promotes the development of spasmolytic polypeptide expressing metaplasia (SPEM) in the stomach. Galectin-3 is abnormally expressed alongside sulfated mucins in high-risk precancerous conditions like Barrett's esophagus and intestinal metaplasia. The findings suggest galectin-3 may represent a therapeutic target for preventing progression from normal tissue to metaplastic and potentially cancerous states.